ISRCTN31974125进行中（未招募）1 期
A phase I double-blind, placebo controlled (part B only), randomised trial to evaluate the safety, tolerability and pharmacokinetics of single dose in fed state, and repeated doses of DNDI-6899 in healthy participants.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 36
- 主要终点
- To evaluate the safety and tolerability the participant will be monitored after taking IMP and at various timepoints after. Vital signs will also be taken regularly.1.Adverse events2.Clinically important laboratory values3.PCI vital signs4.12 lead electrocardiogram (ECG) findings5.24 hours (hr) telemetry and Holter findings6.Physical examination findings
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.Participants must be 18 to 55 years of age inclusive, at the time of signing the informed consent and can be included in only one cohort of this trial. 2.Participants must be healthy as determined by the Investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. 3.Body weight =50 kg and body mass index (BMI) within the range 18.5 -30 kg/m² (inclusive). 4.Male Participants: Male participants with partners of childbearing potential must use either one of the male or female condom, with the female partner using an additional highly effective contraceptive method with a failure rate of <1% per year, during the treatment period, and for at least 90 days after the last dose of trial treatment. Other acceptable methods of contraception include: •Any highly effective method of contraception listed below for female participants •Progesterone-only oral contraception, where inhibition of ovulation is not the primary mode of action •Cap, diaphragm, or sponge with spermicide For participants who practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant, contraceptive requirements do not apply. Male participants should refrain from donating sperm during the treatment period and for at least 90 days after the last dose of trial treatment. For participants who are exclusively in same-sex relationships, contraceptive requirements do not apply. 5.Female Participants: Female participants who are of non-childbearing potential (i.e., due to being post menopausal for at least 1 year (confirmed by FSH assessment) or permanently sterile following hysterectomy, bilateral salpingectomy, bilateral oophorectomy) will not be required to use contraception. Female participants of childbearing potential must be willing to use a highly effective method of birth control (i.e. contraceptive measure with a failure rate of <1% per year when used consistently and correctly, as per described in protocol) with low user dependency, in conjunction with a barrier contraception (i.e. either one of the male or female barrier contraceptions) from the time of screening until 30 days after the final Follow up Visit. Use of any of the protocol defined contraception should have been established for at least 90 days prior to enrolment (the investigator should evaluate the potential for contraceptive method failure (e.g. non-compliance, recently initiated) in relationship to the first dose of trial treatment. Highly effective methods of contraception include: •Placement of intrauterine device or intrauterine system. •Established use of oral, injected or implanted hormonal methods of contraception associated with inhibition of ovulation. •Male sterilisation (with the appropriate post-vasectomy confirmation of surgical success). For female participants on the trial, the vasectomised male partner should be the sole partner for that participant. •Bilateral tubal ligation For participants who practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant, contraceptive requirements do not apply. For participants who are exclusively in same-sex relationships, contraceptive requirements do not apply.6.Willing to participate in the trial and capable of giving signed informed consent.
排除标准
- •1.History or presence of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the trial treatment; or interfering with the interpretation of data in the opinion of the investigator. 2.Previous history of leishmaniasis 3.Alanine transaminase (ALT) or Aspartate aminotransferase (AST) >upper limit of normal (ULN) confirmed by repeat assessment. 4.Bilirubin >ULN confirmed by repeat assessment. Participants with known Gilbert’s syndrome with total bilirubin < 1.5xULN are eligible to participate in the study. 5.Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones) 6.Current or past history of clinically significant gastritis or gastroduodenal ulcers 7.Regular use of non-steroidal anti-inflammatory drugs (NSAID) 8.QTcf >450 msec for male and 470 msec for female 9.Loss of blood or blood products in excess of 500 mL within a 56-day period. 10.The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current trial: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer). 11.Sensitivity to any of the trial treatments, or components or drug or other allergy that, in the opinion of the Investigator or DNDi Medical Monitor, contraindicates participation in the trial. 12.Regular use of known drugs of abuse. 13.Participants with an estimated GRF (calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation) of = 80ml/min/1.73m2 or with significant hematuria or proteinuria (+or higher)on urinary dipstick testing. 14.Presence of Hepatitis B surface antigen (HBsAg) or positive Hepatitis C antibody test result at screening. 15.Positive human immunodeficiency virus (HIV) antibody test. 16.Positive pre-trial drug/alcohol screen (confirmed by repeat exam). 17.Clinically significant proteinuria and or haematuria, defined as positive urine dipstick test (1+). Urine dipstick should be repeated at least 3 days apart in case of urine dipstick test trace reading on previous occasion. 18.Participants with Spot urine protein creatinine ratio >0.5 will be excluded. 19.History or regular use of tobacco or nicotine-containing products within 3 months prior to screening. 20.Systolic BP of less than or equal to
- •21.Use of vitamins, herbal therapies, minerals, supplements during 14 days before the first dose of trial medication (except St John’s Wort). Prescription medicine during the 14 days before the first dose of trial medication or use of an over-the-counter medicine during the 14 days before the first dose of trial medication (with the exception of the oral contraceptive pill or up to 2g of paracetamol daily). 22.Participants must not have travelled to an area (as determined by the investigator) with a high prevalence of leishmanial/parasitic infections in the 6 months before screening or intend to do so in the 3 months after the final dose of trial treatment. 23.Food Effect part only: Participant must have no dietary restrictions (e.g., lactose intolerance) or inability to eat an adapted standard meal (includes 35-40% fat content). 24.Food Effect part o
结局指标
主要结局
To evaluate the safety and tolerability the participant will be monitored after taking IMP and at various timepoints after. Vital signs will also be taken regularly.1.Adverse events2.Clinically important laboratory values3.PCI vital signs4.12 lead electrocardiogram (ECG) findings5.24 hours (hr) telemetry and Holter findings6.Physical examination findings
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
A Phase Ib, double-blind, randomized, placebo-controlled trial in genotype 1 HCV-infected patients to determine the safety, tolerability, pharmacokinetics and antiviral activity of repeated doses of TMC649128 given as monotherapy and given in combination with pegylated interferon + ribavirihepatitis C10047438liver diseaseNL-OMON35874PRA International EDS30
已完成
1 期
A blinded study in healthy volunteers to evaluate the safety of the test medicine and compare how the test medicine behaves when the dosage is increased, and when taken alone or alongside salbutamol (albuterol)Cystic fibrosis (CF)Nutritional, Metabolic, EndocrineCystic fibrosisISRCTN30841680F. Hoffman-La Roche Ltd.41
已完成
不适用
A phase 1b, randomized, double-blinded, placebo-controlled study of hydroxychloroquine in outpatient adults with COVID-19CoronaCOVID-1910047438NL-OMON49040Sanofi-aventis20
进行中（未招募）
不适用
A clinical trial of antibody GSK1070806 in the treatment of patients with moderate to severe Crohn’s diseaseCrohn's diseaseISRCTN11093445niversity of Birmingham5
进行中（未招募）
1 期
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b when added to standard of care anticoagulation therapy in Subjects With Acute Submassive Pulmonary EmbolismDS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including Pulmonary Embolism (PE)MedDRA version: 20.0 Level: HLT Classification code 10037379 Term: Pulmonary embolism and thrombosis System Organ Class: 100000004866MedDRA version: 20.0 Level: PT Classification code 10037377 Term: Pulmonary embolism System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-005211-32-NLDaiichi Sankyo, Inc.116